Wilfried Eberhardt
Impact in
- Pulmonary and Respiratory Medicine top 0.05%
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Occupational and environmental lung diseases
- Brain Metastases and Treatment
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
Papers in
-
- Lung Cancer Diagnosis and Treatment 112
- Lung Cancer Treatments and Mutations 74
- Occupational and environmental lung diseases 16
- Brain Metastases and Treatment 5
- Oncology 63
- Lung Cancer Research Studies 20
- Cancer Immunotherapy and Biomarkers 19
- Cancer Treatment and Pharmacology 7
- Co-authors
- Georgios Stamatis (50 shared papers)Martin Stuschke (62 shared papers)Robert Pirker (8 shared papers)Filippo de Marinis (5 shared papers)Joachim von Pawel (9 shared papers)Christoph Pöttgen (35 shared papers)Kenneth John O'Byrne (4 shared papers)Rodryg Ramlau (3 shared papers)
- Journals
- Journal of Thoracic Oncology (39 papers)Annals of Oncology (31 papers)Lung Cancer (22 papers)European Journal of Cancer (18 papers)Journal of Clinical Oncology (13 papers)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Wilfried Eberhardt
247 papers receiving 25.1k citations
Wilfried Eberhardt's Hit Papers
Peers
Comparison fields: 5 of 129
- Pulmonary and Respiratory Medicine 13.7k
- Oncology 9.4k
- Cancer Research 1k
- Radiology, Nuclear Medicine and Imaging 1k
- Immunology 735
Countries citing papers authored by Wilfried Eberhardt
This map shows the geographic impact of Wilfried Eberhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wilfried Eberhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wilfried Eberhardt more than expected).
Fields of papers citing papers by Wilfried Eberhardt
This network shows the impact of papers produced by Wilfried Eberhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wilfried Eberhardt. The network helps show where Wilfried Eberhardt may publish in the future.
Co-authors
The 25 scholars most cited alongside Wilfried Eberhardt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 262 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Hit paper breakdown → | 2015 | 7161 |
| 2 | The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer Hit paper breakdown → | 2016 | 3544 |
| 3 | Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Hit paper breakdown → | 2009 | 1123 |
| 4 | Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) Hit paper breakdown → | 2017 | 741 |
| 5 | The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer Hit paper breakdown → | 2016 | 597 |
| 6 | EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Hit paper breakdown → | 2011 | 489 |
| 7 | Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2021 | 483 |
| 8 | Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2013 | 455 |
| 9 | 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up Hit paper breakdown → | 2014 | 416 |
| 10 | Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hit paper breakdown → | 2013 | 411 |
| 11 | The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer Hit paper breakdown → | 2017 | 389 |
| 12 | Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial Hit paper breakdown → | 2015 | 363 |
| 13 | 2010 | 352 | |
| 14 | 2015 | 335 | |
| 15 | The IASLC Lung Cancer Staging Project Hit paper breakdown → | 2015 | 313 |
| 16 | 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer Hit paper breakdown → | 2015 | 312 |
| 17 | 2015 | 272 | |
| 18 | 1998 | 258 | |
| 19 | 2014 | 250 | |
| 20 | 2016 | 216 |
About Wilfried Eberhardt
Wilfried Eberhardt is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Radiology, Nuclear Medicine and Imaging, Cancer Research and Pharmacology, having authored 262 papers that have together received 25.8k indexed citations. Recurring topics across this work include Lung Cancer Diagnosis and Treatment (112 papers), Lung Cancer Treatments and Mutations (74 papers), Lung Cancer Research Studies (20 papers), Cancer Immunotherapy and Biomarkers (19 papers), Occupational and environmental lung diseases (16 papers), Cancer Treatment and Pharmacology (7 papers), Medical Imaging Techniques and Applications (6 papers) and Brain Metastases and Treatment (5 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (13.7k citations), Oncology (9.4k citations), Cancer Research (1k citations), Radiology, Nuclear Medicine and Imaging (1k citations) and Immunology (735 citations). Wilfried Eberhardt has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Georgios Stamatis, Martin Stuschke, Robert Pirker, Filippo de Marinis, Joachim von Pawel, Christoph Pöttgen, Kenneth John O'Byrne, Rodryg Ramlau, Maciej Jerzy Krzakowski and Jose R. Pereira. Their work appears in journals such as Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer, European Journal of Cancer and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.